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Introduction
With the increasing average lifespan of humans, Alzheimer’s 
disease (AD) is the most common neurodegenerative 
disorder among elderly individuals. It accounts for up to 
80% of all dementia cases and ranks as the fourth leading 
cause of death amongst those above 65 years of age [1]. 
Although the hallmark lesions of the disease were already 
described by Alois Alzheimer in 1906 - amyloid-β (Aβ)-
containing plaques and microtubule-associated protein 
tau-containing neuroﬁ brillary tangles (NFTs) - the 
underlying molecular mechanisms that cause the forma-
tion of these end-stage lesions are not known [2]. 
Moreover, as only a small fraction of AD is caused by 
autosomal dominant mutations, this comes down to a 
question of what is causing the prevalent sporadic cases 
in the ﬁ rst place. A growing body of evidence supports 
mitochondrial dysfunction as a prominent and early, 
chronic oxidative stress-associated event that contributes 
to synaptic abnormalities and, ultimately, selective neur-
onal degeneration in AD [3-9]. Is oxidative stress 
accelerating the NFT and Aβ pathologies, are these 
lesions causing oxidative stress themselves, or are there 
other mechanisms involved? Within the past few years, 
several cell culture models as well as single, double and, 
more recently, triple transgenic mouse models have been 
developed that reproduce diverse aspects of AD. Th ese 
models help in understanding the pathogenic mecha-
nisms that lead to mitochondrial failure in AD, and in 
particular the interplay of AD-related cellular modiﬁ -
cations within this process [10].
Mitochondria: paradoxical organelles
Mitochondria play a pivotal role in cell survival and death 
by regulating both energy metabolism and apoptotic 
pathways (Figure 1); they contribute to many cellular 
functions, including intracellular calcium homeostasis, 
the alteration of the cellular reduction-oxidation poten-
tial, cell cycle regulation and synaptic plasticity [11]. Th ey 
are the ‘powerhouses of cells’, providing energy via ATP 
generation, which is accomplished through oxidative 
phosphorylation from nutritional sources [12]. Neurons 
have particularly high numbers of mitochondria, and 
they are especially enriched in synapses. Due to their 
limited glycolytic capacity, neurons are highly dependent 
on mitochondrial function for energy production [13]. 
However, when mitochondria fulﬁ l their physiological 
function, it is as if Pandora’s box has been opened, as this 
vital organelle contains potentially harmful proteins and 
biochemical reaction centres: mitochondria are the major 
producers of reactive oxygen species (ROS) and at the 
same time targets of ROS toxicity. Th ese include 
Abstract
The pathology of Alzheimer’s disease (AD) is 
characterized by amyloid plaques (aggregates of 
amyloid-β (Aβ)) and neurofi brillary tangles (aggregates 
of tau) and is accompanied by mitochondrial 
dysfunction, but the mechanisms underlying this 
dysfunction are poorly understood. In this review, 
we discuss the critical role of mitochondria and the 
close inter-relationship of this organelle with the 
two main pathological features in the pathogenic 
process underlying AD. Moreover, we summarize 
evidence from AD post-mortem brain as well as cellular 
and animal AD models showing that Aβ and tau 
protein trigger mitochondrial dysfunction through a 
number of pathways, such as impairment of oxidative 
phosphorylation, elevation of reactive oxygen species 
production, alteration of mitochondrial dynamics, and 
interaction with mitochondrial proteins. A vicious cycle 
as well as several vicious circles within the cycle, each 
accelerating the other, can be drawn, emphasizing the 
synergistic deterioration of mitochondria by tau and Aβ.
© 2010 BioMed Central Ltd
Mitochondrial dysfunction - the beginning of 
the end in Alzheimer’s disease? Separate and 
synergistic modes of tau and amyloid-β toxicity
Anne Eckert*1, Karen Schmitt1 and Jürgen Götz2
R E V I E W
*Correspondence: anne.eckert@upkbs.ch
1Neurobiology Laboratory for Brain Aging and Mental Health, Psychiatric University 
Clinics, University of Basel, CH-4012, Basel, Switzerland
Full list of author information is available at the end of the article
Eckert et al. Alzheimer’s Research & Therapy 2011, 3:15 
http://alzres.com/content/3/3/15
© 2011 BioMed Central Ltd
mito chondrial DNA, lipids of the mitochondrial 
membrane, and mitochondrial proteins. Dysregulation of 
mito chon drial function because of these insults leads to 
synaptic stress, disruption of synaptic transmission, 
apoptosis and, ultimately, neurodegeneration [14,15]. 
Th us, it is important to understand the mechanisms of 
mitochondrial stress related to the pathogenesis of AD 
and to exploit this insight for developing therapeutic 
strategies for AD.
Evidence of mitochondrial dysfunction in 
post-mortem AD brain and peripheral cells
Mitochondrial dysfunction has been proposed as an 
underlying mechanism in the early stages of AD since 
Figure 1. Amyloid-β-related mitochondrial impairment. Mitochondria were found to be the target for amyloid-β (Aβ), which interacts 
with several proteins, leading to mitochondrial dysfunction. Indeed, Aβ was found in the outer mitochondrial membrane (OMM) and inner 
mitochondrial membrane (IMM) as well as in the matrix. The interaction of Aβ with the OMM aff ects the transport of nuclear-encoded 
mitochondrial proteins, such as subunits of the electron transport chain complex IV, into the organelle via the translocase of the outer membrane 
(TOM) import machinery. Moreover, Aβ disturbs the activity of several enzymes, such as pyruvate dehydrogenase (PDH) and α-ketoglutarate 
dehydrogenase (αKGDH), decreasing NADH reduction, and the electron transport chain enzyme complex IV, reducing the amount of hydrogen that 
is translocated from the matrix to the intermembrane space (IMS), thus impairing the mitochondrial membrane potential (MMP). Taken together, 
these events cause abnormal mitochondrial electron activities, leading to decreased complex V activity and so to a drop in ATP levels, in addition 
to increasing reactive oxygen species (ROS) generation. Moreover, ROS induce peroxidation of several mitochondrial macromolecules, such as 
mitochondrial DNA (mtDNA) and mitochondrial lipids, contributing to mitochondrial impairment in the mitochondrial matrix. The complex of 
Aβ bound to binding alcohol dehydrogenase (ABAD) impairs the binding of NAD+ to ABAD, changes mitochondrial membrane permeability 
and reduces activities of respiratory enzymes, inducing further ROS production and leading to mitochondrial failure. Aβ binding also activates 
Fis1 (fi ssion protein) and promotes increased mitochondrial fragmentation; this increased mitochondrial fragmentation produces defective 
mitochondria that ultimately damage neurons. Furthermore, Aβ binding to cyclophilin D (CypD) enhances the protein translocation to the inner 
membrane, favouring the opening of the mitochondrial permeability transition pore, formed by the adenine nucleotide translocator (ANT) and 
voltage-dependent anion channels (VDACs). Cyt C, cytochrome C; DLP1, dynamin-like protein 1; PDH, pyruvate dehydrogenase; ProAp, pro-
apoptotic factors; SOD, superoxide dismutase; TCA, tricarboxylic acid; TIM, translocase of the inner membrane.
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energy deﬁ ciency is a fundamental characteristic of the 
AD brain [16,17] as well as of peripheral cells derived 
from AD patients [18]. Th e similar ﬁ ndings in peripheral 
tissue highlight the potential of using surrogate tissue in 
the diagnosis of AD (Figure 2).
Brain imaging studies have demonstrated defects in 
glucose use in living AD patients, an abnormality that 
may occur well before the onset of clinical symptoms 
[17]. Furthermore, several lines of evidence suggest that 
mitochondria intervene in the mechanism by which Aβ, 
which is derived from amyloid precursor protein (APP), 
triggers synaptic failure and neuro degeneration. Crucial 
to this ﬁ nding was the notion that both Aβ and the full 
length protein, APP, accumulate within mitochondria in 
the brains of AD patients [6,19-21].
Furthermore, morphometric analyses revealed that 
mito chondria display structural abnormalities, as illus-
trated by the accumulation of mitochondrial DNA and 
proteins in the cytoplasm and vacuoles; this accelerates 
mitochondrial degradation and thereby leads to a 
signiﬁ cant decrease in mitochondrial numbers in AD 
[22]. Th e mitochondrial accumulation of APP and Aβ in 
brain tissues causes both altered activities in key mito-
chon drial enzymes, including cytochrome c oxidase 
(COX, complex IV), pyruvate dehydrogenase (PDH) and 
α-ketoglutarate dehydrogenase complex (αKGDH), and 
import of nuclear-encoded proteins [3,18,21,23]. Th e 
activity of αKGDH, but not of PDH, has been found to be 
reduced in cultured skin ﬁ broblasts from sporadic AD 
patients and in a subset of patients with presenilin-1 
mutations. Sorbi and colleagues [24] observed a reduction 
in PHD, ATP-citrate lyase and acetoacetyl-CoA thiolase 
in post-mortem brain tissues from AD-aﬀ ected subjects 
and correlated the decrease of these enzymes to the 
decreased production of acetyl-coenzyme A and 
cholinergic defects that are observed in AD.
Th e impairment of mitochondrial oxidative phos phory-
lation in the AD brain was found to be proportional to 
clinical disability [3]. Th e most consistent defect in mito-
chondrial electron transport enzymes in AD is a deﬁ ci-
ency in COX, a ﬁ nding reported in AD post-mortem 
brain as well as in platelets and ﬁ broblasts from AD 
patients [25,26]. Dysfunction of COX increases ROS 
produc tion, reduces energy stores, and disturbs energy 
metabolism [27]. Altered levels of antioxidant enzymes, 
such as catalase, copper/zinc superoxide dismutase (Cu/
Zn-SOD) and manganese superoxide dismutase (Mn-
SOD) have been found in AD brain, supporting increased 
oxidative stress as a pathomechanism in AD [28].
Laser-capture microdissection has been applied to 
investigate distinct brain areas as some undergo neuro-
degeneration whereas others do not: the analysis of the 
expression of 80 metabolically relevant nuclear-encoded 
electron transport chain genes from non-NFT-bearing 
AD neurons revealed that 60 to 70% of these were 
signiﬁ cantly lower in metabolically aﬀ ected areas such as 
the posterior cingulate cortex, the middle temporal 
gyrus, and the hippocampal CA1 region [29]. Post-mortem 
tissue also provides strong evidence for increased levels 
of cellular oxidative stress in vulnerable regions of AD 
brains compared to aged controls [30]. Increased protein 
oxidation, protein nitration, and lipid peroxidation were 
Figure 2. Mitochondrial impairment in the brain and peripheral cells of Alzheimer’s disease patients. AD, Alzheimer’s disease; ETC, electron 
transport chain; ROS, reactive oxygen species; TCA, tricarboxylic acid.
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detected in brain areas with overt NFTs and amyloid 
plaques [31].
More recently, abnormal mitochondrial dynamics has 
been identiﬁ ed in ﬁ broblasts from sporadic and familial 
AD cases [32], a distortion probably mediated by altered 
expression of dynamin-like protein 1 (DLP1), a regulator 
of mitochondrial ﬁ ssion and distribution, due to elevated 
oxidative and/or Aβ-induced stress. Moreover, deregu-
lated mitochondrial dynamics might be due to enhanced 
nitrosative stress generated by Aβ, such as S-nitrosylation 
of DLP1 in AD brain [33]. Th is modiﬁ cation can disturb 
the balance between ﬁ ssion and fusion of mitochondria 
in favour of mitochondrial ﬁ ssion followed by mito chon-
drial depletion from axons and dendrites and, subse-
quently, synaptic loss.
Altogether, these data indicate that mitochondrial 
dysfunction is a highly relevant event in AD patho-
physiology. Post-mortem studies in AD brain allow the 
identiﬁ cation of long-term synergistic in vivo eﬀ ects of 
tau and Aβ in human because, in the majority of AD 
cases, both pathologies persist in parallel for many years.
Mitochondrial dysfunction in cellular and 
transgenic mouse AD models
Understanding the molecular pathways by which the 
various pathological alterations including Aβ and tau 
compromise neuronal integrity and lead to clinical 
symptoms has been a long-standing goal of AD research. 
Th e successful development of cell and mouse models 
that mimic diverse aspects of the disease process have 
facilitated this eﬀ ort and assisted in understanding of the 
interplay of Aβ and tau on bioenergetics processes in vivo 
[10] (Figure 3).
Mitochondria and Aβ
Aβ may exert its toxicity via a plethora of pathways and 
thereby induce synaptic and neuronal degeneration [2].
Using neuronal PC12 cells, we found that expression of 
one known APP gene mutation, the ‘Swedish APP 
(APPSw)’ double mutation (KM670/671NL), leads to an 
enhanced vulnerability of these cells to oxidative stress 
and mitochondrial dysfunction, mediated by diﬀ erent 
caspases and the stress-activated protein kinase pathway 
[34-36] (Figure 3). Of note, we are able to study the 
eﬀ ects of Aβ in a dose- dependent manner as cells 
transfected with APPSw had ﬁ vefold higher Aβ levels than 
wild-type APP (APPwt) transfected cells, similar to the 
increase found in human carriers with the APPSw muta-
tion compared to sporadic AD cases. Th e data suggest 
that the mitochondrial dysfunction induced by Aβ is 
probably mediated via enhanced nitric oxide production 
that reduces complex IV activity. Th is reduction leads to 
a depletion of intracellular ATP levels, ﬁ nally initiating 
cell death [37]. When intracellular Aβ production is 
prevented by a γ-secretase inhibitor, this restores nitric 
oxide and ATP levels, indicating a direct involvement of 
Aβ in these mechanisms.
Mitochondria were found to be a target for APP 
toxicity as both the full-length protein and Aβ accumulate 
in the mitochondrial import channels, and both lead to 
mitochondrial dysfunction. Recently, APP has been 
demonstrated as a substrate of the mitochondrial γ-
secretase in cultured SH-SY5Y human neuroblastoma 
cells [38]. Pavlov and colleagues [38] proposed that APP 
processing in mitochondria may lead to local Aβ pro-
duction, thereby contributing to mitochondrial dysfunc-
tion. Recently, our group investigated speciﬁ c eﬀ ects of 
Aβ on mitochondrial function under physiological 
conditions by analysing mitochondrial respiratory func-
tion and energy homeostasis in both control and APPwt-
expressing SH-SY5Y cells [8]. One possibility as to how 
chronic exposure to soluble Aβ may result in an impair-
ment of energy homeostasis is through decreased respira-
tory capacity of the mitochondrial respiratory chain, 
mainly of complex IV, which, in turn, may accelerate 
neuronal demise.
Eventually, APP, through Aβ production, causes an 
imbalance of mitochondrial ﬁ ssion/fusion that results in 
mitochondrial fragmentation and abnormal distribution, 
which contributes to mitochondrial and neuronal dys-
func tion [39].
An interesting observation was made when the toxic 
eﬀ ects of Aβ were compared with human amylin (HA), a 
protein aggregating in the pancreas of type 2 diabetic 
patients [40]. Both agents share amyloidogenic properties 
and are toxic to primary neuronal cultures, whereas the 
non-amyloidogenic rat amylin is not [41]. In a next step, 
HA and Aβ toxicity to SH-SY5Y neuroblastoma cells was 
assessed by iTRAQ quantitative proteomics [42]. Th is 
revealed the surprising observation that identical proteins 
are deregulated by HA and Aβ, but not rat amylin, and a 
quarter of these were mitochondrial, supporting the 
notion that mitochondrial dysfunction is a common 
target in these two amyloidoses. Functional validation 
revealed that Aβ and HA both exert a shared toxicity, at 
least in part, via deregulation of identical mitochondrial 
proteins and impairment of complex IV activity [42].
AD is believed to be a disease of the synapses, charac-
terized by massive synaptic and, eventually, neuronal 
loss, and these features have been detected in AD 
transgenic mouse models (Figure 3). A decrease of the 
mitochondrially localized chaperone hsp70, which 
stabilizes proteins during their import into mitochondria, 
has been observed in synaptosomal fractions derived 
from the APPSw transgenic strain Tg2576, pointing to a 
mito chondrial stress response [43]. Signiﬁ cant diﬀ er-
ences were revealed in the protein subunit composition 
of respiratory chain complexes I and III. Moreover, 
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endo genous Aβ was found to be associated with brain 
mitochondria in these mice. Cu2+ ions have been shown 
to render Aβ more toxic, possibly in its dimeric con-
formation, as a potent inhibitor of COX, thereby contri-
but ing to neurodegeneration in AD [44]. In APPSw trans-
genic mice, reduced glucose metabolism was observed 
after [14C]-2-deoxyglucose infusion as well as impaired 
Cu/Zn SOD activity, both of which contribute to 
oxidative damage. In another transgenic mouse model, 
APPS/L, which combines the Swedish (K670M/N671L) 
with the London (V717I) mutation in the human APP 
gene, an early energy dysfunction was found as shown by 
a decreased mitochondrial membrane potential as well as 
decreased ATP levels at 3 months of age, when Aβ levels 
are elevated but plaques are not yet present [5,14,37]. A 
stronger reduction in mitochondrial membrane potential 
and in ATP levels was found in double transgenic APP/
PS1 (APPS/L/PS1 M141L) mice, which generate higher 
levels of Aβ compared to their single transgenic litter-
mates (APPS/L), and exhibit Aβ plaques already at an age 
of 3 months [4]. Together, this implies that an Aβ-
dependent mitochondrial dysfunction starts at a very 
young age and accelerates substantially with increasing 
age, as does the Aβ plaque load [4]. Consistent with this 
observation, APP/PS2 (APPSw/PS2 N141I) double trans-
genic mice display age-related cognitive deﬁ cits asso-
ciated with discrete brain Aβ deposition and inﬂ am-
mation [45]. Furthermore, an Aβ insult in APPS/L mice 
caused early deﬁ cits in synaptic mitochondria, as shown 
by increased mitochondrial permeability transition, a 
decline in both respiratory function and activity of COX, 
and increased mitochondrial oxidative stress [46].
Of note, age-dependent impairment of oxygen con-
sump tion, such as a decrease of state 3 and of uncoupled 
respiration, was observed in several APP transgenic 
mouse models compared to aged-matched controls 
[5,14,43,47]. Th is indicates that mitochondrial deregula-
tion is a common feature in Aβ-generating mice and 
independent of the mouse model used.
Th ere is broad experimental proof that Aβ is indeed 
present in mitochondria. Aβ binds speciﬁ cally to the 
mitochondrial Aβ-binding alcohol dehydrogenase (ABAD) 
[6], a mitochondrial matrix protein that is up-regulated 
in the temporal lobe of AD patients as well as in APP 
Figure 3. Mitochondrial impairment in Alzheimer’s disease cell culture and transgenic mice models. The successful development of 
Alzheimer’s disease (AD) cell culture models as well as single, double and triple transgenic mice models that mimic diverse aspects of the disease 
have been helpful in understanding the pathogenic mechanisms on bioenergetic processes in vivo, particularly the interplay of AD-related 
amyloid-β (Aβ) and tau proteins, leading to the mitochondrial failures underlying AD. APP, amyloid precursor protein; LTP, long-term potentiation; 
MMP, mitochondrial membrane potential; NO, nitric oxide; PDH, pyruvate dehydrogenase; ROS, reactive oxygen species.
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transgenic mice [48]. Th e Aβ-ABAD interaction causes 
elevated ROS production, cell death, as well as spatial 
learning and memory deﬁ cits in 5-month-old APP/
ABAD double transgenic mice [49]. Th e investigation of 
the crystal structure of ABAD-Aβ demonstrated that the 
formation of the complex prevents the binding of NAD+ 
to ABAD, thereby changing the mitochondrial membrane 
permeability and reducing the activities of respiratory 
enzymes, which then may lead to mitochondrial failure 
[6]. Aβ in mitochondria further interacts with cyclophilin 
D (CypD), an integral part of the mitochondrial permea-
bility transition pore that potentiates free radical produc-
tion, causes synaptic failure, and promotes opening of the 
pore leading to apoptosis [50]. It has been demonstrated 
previously that CypD is capable of forming complexes 
with Aβ within mitochondria of cortical neurons from 
APP mutant mice, increasing the translocation of CypD 
from the matrix to the inner membrane. Furthermore, in 
APP transgenic mice, the abrogation of CypD was 
capable of attenuating Aβ-mediated abnormal mitochon-
drial dysfunction, such as calcium-induced mitochondrial 
swelling, and it lowered mitochondrial calcium uptake 
capacity and impaired mitochondrial respiratory func-
tion. Aβ impaired calcium storage in mitochondria, alter-
ing neuronal function, as it is exported to the cytosol, 
together with other apoptotic factors (ProAp), such as 
cytochrome c (Figure 1). Finally, Anandatheerthavarada 
and Devi [51] showed that APP contains a mitochondrial 
targeting sequence and that an accumulation of APP in 
mitochondrial membranes leads to mitochondrial dys-
func tion in Tg2576 neurons. Taken together, these ﬁ nd-
ings are in line with the recently proposed hypothesis of 
an intracellular Aβ toxicity cascade, which suggests that 
the toxic Aβ species that cause molecular and bio-
chemical abnormalities are in fact intracellular oligo-
meric aggregates rather than the extracellular, insoluble 
plaques [6,20].
Mitochondria and tau protein
How does tau interfere with mitochondrial function? In 
its hyperphosphorylated form, tau, which forms the 
second hallmark lesion in AD, the NFTs, has been shown 
to block mitochondrial transport, which results in energy 
deprivation and oxidative stress at the synapse and, 
hence, neurodegeneration [52-55]. In transgenic pR5 
mice that overexpress human P301L mutant tau [56], the 
biochemical consequences of tau pathology have been 
intensively investigated using proteomics followed by 
functional validation [57,58]. A mass-spectrometric 
analy sis of the brain proteins from these mice revealed 
mainly a deregulation of mitochondrial respiratory chain 
complex components (including complex V), antioxidant 
enzymes, and synaptic proteins (Figure 4). Th e functional 
analysis demonstrated a mitochondrial dysfunction in 
the mice, together with reduced NADH-ubiquinone 
oxido reductase (complex I) activity and, with age, 
impaired mitochondrial respiration and ATP synthesis. 
Mitochondrial dysfunction was associated with higher 
levels of ROS in aged transgenic mice. Increased tau 
pathology as in aged homozygous pR5 mice revealed 
modiﬁ ed lipid peroxidation levels and the upregulation of 
antioxidant enzymes in response to oxidative stress [57]. 
Th us, this evidence demonstrated for the ﬁ rst time that 
not only Aβ but also tau pathology can lead to metabolic 
impairment and oxidative stress as in AD.
Consistent with observations of a cytosolic accumu la-
tion of the α-chain of ATP synthase observed at early 
stages of neuroﬁ brillary degeneration in AD, one mecha-
nism proposed is that tau accumulation could have direct 
consequences on mitochondrial activity through the 
cytosolic accumulation of the α-chain of ATP synthase. 
Reciprocally, hyperphosphorylation of tau may be 
directly attributable to mitochondrial oxidative stress in a 
mouse model lacking the mitochondrial detoxifying 
enzyme superoxide dismutase 2 (Sod2−/−), consistent with 
a synergistic interaction of APP and mitochondrial 
oxidative stress in contributing to an AD-like neocortical 
pathology [59]. Furthermore, chronic respiratory chain 
dysfunction through inhibition of complex I led, besides 
a concentration-dependent decrease in ATP levels, to a 
redistribution of tau from the axon to the cell body, the 
retrograde transport of mitochondria and, ﬁ nally, cell 
death [60]. Together, these ﬁ ndings support the notion 
that tau pathology involves a mitochondrial and oxidative 
stress disorder possibly distinct from that caused by Aβ.
Pathogenic convergence of Aβ and tau on mitochondria
Although Aβ and tau pathologies are both known hall-
marks in AD, the underlying mechanisms of the interplay 
between plaques and NFTs (or Aβ and tau) have 
remained unresolved. However, a close relationship 
between mitochondrial impairment and Aβ on the one 
hand and tau on the other has been established. How do 
both features in AD relate to each other and might the 
two molecules synergistically aﬀ ect mitochondrial inte-
grity? Several studies suggest that Aβ aggregates and 
hyper phosphorylated tau may block mitochondrial 
carriage to the synapse, leading to energy defects and 
neuro degeneration [61]. Moreover, transport of APP into 
axons and dendrites may be inhibited by enhanced tau 
levels, causing impaired axonal transport, which suggests 
a link between tau and APP [52,55]. Remarkably, Aβ 
injections amplify a pre-existing tau pathology in several 
transgenic mouse models [56,62,63], whereas lack of tau 
abrogates Aβ toxicity [54,64]. Our ﬁ ndings indicate that 
mitochondria in tau transgenic pR5 mice display en-
hanced vulnerability towards Aβ insult in vitro [57,65], 
suggesting a synergistic action of tau and Aβ pathologies 
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on this organelle (Figure 3). Th e Aβ insult caused a 
greater reduction of mitochondrial membrane potential 
in cerebral cells from pR5 mice [57]. Furthermore, 
incubation of isolated mitochondria from pR5 mice with 
either oligomeric or ﬁ brillar Aβ preparations resulted in 
impairment of the mitochondrial membrane potential 
and of respiration. Interestingly, aging particularly 
increased the sensitivity of mitochondria to oligomeric 
Aβ insult compared to that of ﬁ brillar Aβ. Th is suggests 
that while both oligomeric and ﬁ brillar Aβ are toxic, they 
exert diﬀ erent degrees of toxicity [65]. In a related study, 
Crouch and colleagues [66] demonstrated that increasing 
the bioavailability of intracellular copper can restore 
cognitive function by inhibiting the accumulation of 
neurotoxic Aβ trimers and phosphorylated tau in APPSw/
PS1 transgenic mice. In yet another study, it was shown 
that exposure to Aβ induces tau hyperphos phory lation 
by promoting glycogen synthase kinase (GSK)3β activity. 
Th is demonstrates an intimate relationship between Aβ 
accumulation and abnormal tau phosphory lation in 
causing the cognitive deﬁ cits that characterize AD, and 
highlights GSK3β activity as an important intermediate 
[67]. In contrast, overexpression of the longest form of 
human wild-type tau (tau441) in mouse neuroblastoma 
(N2A) showed an anti-apoptotic protec tive function of 
tau phosphorylation, which likely inhibited competitively 
phosphorylation of β-catenin by GSK-3β, facilitating the 
function of β-catenin. Th us, overexpression of tau seems 
to attenuate Aβ-mediated cell death via suppression of 
the mitochondria-caspase-3 pathway [68,69]. Taken 
together, these studies illustrate a complex interplay 
between the two key proteins in AD.
In a step further, triple transgenic mouse models have 
recently been established that combine Aβ and tau 
pathologies, and the contributions of both AD-related 
proteins to the mitochondrial respiratory machinery and 
energy homeostasis have been investigated in vivo 
(Figure 3). Indeed, our group demonstrated a mitochon-
drial dysfunction in a novel triple transgenic mouse 
model (pR5/APPSw/PS2 N141I) - tripleAD mice - using 
proteomics followed by functional validation [9]. Notably, 
deregulation of complex I was found to be tau-dependent, 
while deregulation of complex IV was Aβ-dependent, at 
both the protein and activity level (Figure  5). Whereas 
down-regulation of several subunits of complex I was 
observed in tripleAD mice compared to both pR5 and 
Figure 4. Diff erential expression of ascertained subunits of the electron transport chain. A quantitative mass-tag labelling proteomic 
technique, iTRAQ, and mass-spectrometric analysis of the brain proteins from single, double and triple transgenic mouse models revealed massive 
deregulation of 24 components mainly related to the mitochondrial respiratory chain complex (including complex V), antioxidant enzymes, and 
synaptic proteins. Functional analysis validated the proteomic approach by confi rming the strongest defects of the respiratory capacity mainly 
at complexes I, IV and V in transgenic mice, at both the protein and activity level. Signifi cantly changed expression of nuclear- encoded (Ndufs2, 
Ndufs8, Ndufb10, IV, Va, Vb, VIIa and D) and mitochondrial-encoded (COX II) complex subunits are highlighted in red. Complex I subunits: Ndufs2, 
NADH dehydrogenase (ubiquinone) Fe-S protein 2; Ndufs8, NADH dehydrogenase (ubiquinone) Fe-S protein 8; Ndufb10, NADH dehydrogenase 
(ubiquinone) 1 alpha subcomplex 10. Complex IV subunits: II, Cytochrome c oxidase subunit 2; IV, Cytochorme c oxidase subunit IV isoform 1; Va, 
Cytochrome c oxidase polypeptide Va; Vb, Cytochrome c oxidase polypeptide Va; VIIa, Cytochrome c oxidase polypeptide VIIa- liver/heart. Complex 
V subunits: D, ATP synthase D chain. IMM, inner mitochondrial membrane; IMS, intermembrane space.
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APPSw/PS2 mice, deregulation of several subunits of 
complex V was seen in tripleAD mice compared to pR5 
mice but not compared to APPSw/PS2 mice (Figure 4). 
Th e convergent eﬀ ects of Aβ and tau led already at the 
age of 8 months to depolarized mitochondrial membrane 
poten tial in tripleAD mice. Additionally, we found that 
age-related oxidative stress at 12 months of age may 
exaggerate the disturbances in the respiratory system and 
synthesis of ATP and, in turn, take part in the vicious 
cycle that ﬁ nally leads to cell death.
Together, our studies highlight the key role of mito-
chon dria in AD pathogenesis, and the close interrelation-
ship of this organelle and the two main pathological 
hallmarks of this disease. Our data complement those 
obtained in another triple transgenic mouse model, 3xTg-
AD (P301Ltau/APPSw/PS1 M146L) [70]. Mitochondrial 
dysfunction was evidenced by age-related decreased 
activity of regulatory enzymes of the oxidative phos-
phory lation system, and of PDH and COX in 3xTg-AD 
mice aged from 3 to 12 months [71]. Th ese mice also 
exhibited increased oxidative stress and lipid peroxida-
tion. Most of the eﬀ ects on mitochondria were seen at 
the age of 9 months, whereas mitochondrial respiration 
was signiﬁ cantly decreased at 12 months of age. Impor-
tantly, mitochondrial bioenergetics deﬁ cits were found to 
precede the development of AD pathology in the 
3xTg-AD mice. More recently, Hyun and colleagues [72] 
demonstrated that the plasma membrane redox system 
(PMRS) is impaired in the 3xTg-AD mice and that the 
activities of PMRS enzymes may protect neurons against 
Aβ toxicity, suggesting enhancement of PMRS function 
as a novel approach for protecting neurons against 
oxidative damage in AD and related disorders. Collec-
tively, these recent data consolidate the idea that a 
synergistic eﬀ ect of tau and Aβ augments the pathological 
deterioration of mitochondria at an early stage of AD.
Conclusion
We discuss here the critical role of mitochondria and the 
close inter-relationship of this organelle with the two 
main pathological features in the pathogenic process 
underlying AD.
Mitochondrial impairment has been recognized as a 
prominent and early event in AD in terms of metabolic 
energy production associated with respiratory chain dys-
function and the regulation of levels of second messen-
gers such as ROS or Ca2+. Th is is partially due to either 
accumulated damage to mitochondrial DNA or direct 
harmful eﬀ ects of oxidative stress and/or Aβ on mito-
chondrial components. Also, mitochondrial traﬃ  cking as 
well as mitochondrial fusion/ﬁ ssion are known to be 
altered in AD, compromising normal neurophysiology 
Figure 5. Impairment of the electron transport chain in Alzheimer’s disease. Complexes I (NADH:ubiquinone oxidoreductase) and II (succinate 
dehydrogenase, belongs to the tricarboxylic acid (TCA) cycle) receive electrons from NADH and FADH2, respectively. Electrons are then driven 
from complexes by the mobile carrier molecules coenzyme Q/ubiquinone (UQ) and cytochrome c (Cyt c) to the fi nal acceptor, molecular oxygen 
(O2). Electron fl ow is coupled to proton movement across the inner mitochondrial membrane (IMM) in complexes I, III and IV. The resulting proton 
gradient is harvested by complex V to generate ATP. In Alzheimer’s disease, abnormal mitochondrial electron activities have been observed, 
predominantly in complexes I and IV, leading to impaired mitochondrial membrane potential, decreased production of ATP (complex V) and 
enhanced reactive oxygen species (ROS) levels. Interestingly, deregulation of complex I is mainly tau-dependent, while deregulation of complex IV 
is amyloid-β (Aβ)-dependent, at both the protein and activity level. IMS, intermembrane space.
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and a healthy cellular mitochondrial pool, which even-
tually leads to apoptosis. Speciﬁ cally, the mitochondrial 
impairment integrates the close interplay of the two 
common hallmarks of AD, plaques and NFTs, or Aβ and 
tau, which act independently as well as synergistically on 
this vital organelle. With regards to the involvement of 
AD-related proteins in pathogenesis, a vicious cycle as 
well as several vicious circles within the cycle, each 
accelerating the other, can be drawn, emphasizing the 
potency of the synergistic destruction in mitochondria.
Finally, the key role of mitochondrial dysfunction in the 
early pathogenic pathways by which Aβ leads to neuronal 
dysfunction in AD is particularly challenging with 
respect to establishing therapeutic treatments. Besides 
the modulation and/or removal of both Aβ and tau 
pathology, strategies involving eﬀ orts to protect cells at 
the mitochondrial level by stabilizing or restoring mito-
chondrial function or by interfering with energy 
metabolism appear to be promising; these eﬀ orts also 
emphasize the importance of mitochondria in the 
pathogenesis of AD. Cellular models for AD as well as 
transgenic mice, and particularly triple transgenic models 
that combine both pathologies, are valuable tools in 
monitoring therapeutic interventions at the mitochon-
drial level. Eventually, this may lead to therapies that 
prevent the progression of Aβ deposits and tau hyper-
phosphorylation at an early stage of disease.
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